.
MergerLinks Header Logo

Announced

Completed

Baring Private Equity Asia completed a $100m investment in Hutchison China MediTech.

Financials

Edit Data
Transaction Value£72m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

Single Bidder

Acquisition

Minority

Completed

Hong Kong

Pharmaceuticals

biopharmaceuticals

Private Equity

Domestic

Friendly

Synopsis

Edit

Baring Private Equity Asia, a private equity firm, completed a $100m investment in Hutchison China MediTech, a biopharmaceutical company. “With this strategic investment, BPEA is demonstrating our long-term commitment to HUTCHMED, an emerging biopharma leader in Asia. The healthcare sector in China is a core area of investment focus for BPEA. HUTCHMED is developing and delivering highly differentiated oncology therapies to patients around the world and we look forward to working with the CEO and management team to support the company’s innovation and global growth aspirations," Jean Eric Salata, BPEA CEO and Founding Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US